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inhibition of the Atp synthase 
sensitizes Staphylococcus aureus 
towards human antimicrobial 
peptides
Liping Liu1, christian Beck2, Katrine nøhr‑Meldgaard1, Andreas peschel2, 
Dorothee Kretschmer2, Hanne ingmer1* & Martin Vestergaard1
Antimicrobial peptides (AMps) are an important part of the human innate immune system for 
protection against bacterial infections, however the AMps display varying degrees of activity against 
Staphylococcus aureus. previously, we showed that inactivation of the Atp synthase sensitizes 
S. aureus towards the AMp antibiotic class of polymyxins. Here we wondered if the Atp synthase 
similarly is needed for tolerance towards various human AMPs, including human β-defensins (hBD1-
4), LL-37 and histatin 5. Importantly, we find that the ATP synthase mutant (atpA) is more susceptible 
to killing by hBD4, hBD2, LL-37 and histatin 5 than wild type cells, while no changes in susceptibility 
was detected for hBD3 and hBD1. Administration of the ATP synthase inhibitor, resveratrol, sensitizes 
S. aureus towards hBD4-mediated killing. Neutrophils rely on AMPs and reactive oxygen molecules 
to eliminate bacteria and the atpA mutant is more susceptible to killing by neutrophils than the Wt, 
even when the oxidative burst is inhibited.these results show that the staphylococcal Atp synthase 
enhance tolerance of S. aureus towards some human AMps and this indicates that inhibition of the 
Atp synthase may be explored as a new therapeutic strategy that sensitizes S. aureus to naturally 
occurring AMps of the innate immune system.
Bacterial pathogens that cause disease in humans remain a serious threat to public health and antibiotics are still 
our primary weapons in treating many bacterial diseases. The ability to eradicate bacterial infections is however 
challenged by development of resistance for every type of antibiotic introduced to the  clinic1. The majority of 
the new small molecule antibiotics in clinical development are however inhibiting the same targets as already 
marketed  antibiotics2. As an alternative to small molecule antibiotics, antimicrobial peptides (AMPs) are also 
explored in clinical trials, however most of the AMPs are only tested for topical applications due to toxicity issues 
and low metabolic  stability3. Here we propose a new strategy to combat bacterial infections, namely to sensitize 
bacteria to the naturally occurring antimicrobial peptides of the human body and hence boosting the antibacte-
rial capabilities of the innate immune system to eradicate bacterial infections.
Humans are continuously exposed to numerous, and potentially pathogenic, microorganisms, where the 
innate immune system provides the first line of defense. AMPs constitute an important defense mechanism of 
the innate immune system against invading microorganisms, due to their antimicrobial and immune stimulatory 
 properties4,5. In humans, several classes of AMPs have been identified, such as α- and β-defensins, the cathelicidin 
LL-37 and  histatins5. The α-defensins consist of six members, which are divided into human neutrophil peptides 
(HNP1-4) and human α-defensin 5 and 6 (HD5 and HD6). HNP1-4 are highly concentrated in the granules of 
neutrophils, but are also expressed in monocytes, lymphocytes and natural killer cells. HD5 and HD6 are pri-
marily expressed in Paneth cells of the small  intestine4. The β-defensins consist of four members (hBD1-4) and 
are primarily secreted by mucosal surface epithelia, e.g. by keratinocytes in the human  skin6. Histatins comprise 
a family of cationic, histidine-rich peptides that are present in human saliva and are important for maintaining 
open
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oral health by limiting infections in the oral  cavity5. Several histatins have been characterized, however histatin 
5 displays the strongest antimicrobial  activity5. LL-37 is an antimicrobial peptide that belongs to the catheli-
cidin family and is expressed in various epithelial- (e.g. keratinocytes) and immune cells (e.g. neutrophils and 
macrophages)7. The bactericidal activities of many AMPs have generally been attributed to pore formation in 
bacterial cytoplasmic membranes, however this mode of action may be too  simplistic8,9. The bactericidal activity 
of hBD3 has for example been associated with lipid II binding, leading to inhibition of cell wall  biosynthesis10 and 
some AMPs also have intracellular  targets11. Many antimicrobial peptides display a net positive charge, which 
is important in the initial electrostatic attraction to negatively charged bacterial phospholipid membranes and 
negatively charged teichoic acids on the surface of Gram positive bacteria, e.g. Staphylococcus aureus11.
S. aureus is a common colonizer of the human  body6, where approximately 30–50% of healthy adults tran-
siently carry this species and approximately 20% are persistently  colonized12. The skin, nose and intestinal tract 
are important ecological niches for S. aureus  carriage13. Topical colonization with S. aureus imposes a risk for 
subsequent infections, if the skin or mucosal barriers are breached and enables transmission of S. aureus cells to 
the adjacent tissues or the  bloodstream12. S. aureus is an opportunistic pathogen that may cause life-threatening 
diseases, such as sepsis, endocarditis and  pneumonia12. Even though keratinocytes express various antimicrobial 
peptides, such as hBD1-4 and LL-37, S. aureus frequently colonizes human  skin6. Among the human β-defensins, 
only hBD3 displays potent bactericidal activity against S. aureus at physiological  conditions14–16, and keratino-
cytes are dependent on hBD3 for killing of S. aureus17. However, it is incompletely understood, why the remain-
ing β-defensins display limited anti-staphylococcal activity. This indicates that sensitizing S. aureus towards the 
innate immune system AMPs may potentially facilitate eradication of colonizing S. aureus.
Multiple factors affect bacterial susceptibility towards AMPs, such as cell membrane composition, cell sur-
face charge and transmembrane  potential8. The positive charge of many AMPs facilitates the interaction with 
negatively charged bacterial  envelopes11. A common resistance mechanism exploited by bacteria is to reduce 
the net negative charge of the cell envelope, for example by lysinylation of  phospholipids18 and D-alanylation of 
teichoic acids in S. aureus19. Curiously, deficiency of wall teichoic acids selectively confers reduced susceptibil-
ity to hBD3, while not affecting susceptibility to LL-37 and HNP1-320. The transmembrane potential affects the 
ability of cationic AMPs to permeabilize  membranes8,21, where an inside-negative transmembrane potential 
facilitates insertion of some cationic AMPs into bacterial  membranes8. Interference with the electron transport 
chain by inactivation of menaquinone- (men mutants) or hemin (hem mutants) biosynthesis pathways leads to 
membrane depolarization in S. aureus and in the appearance as small colony variants (SCVs) on agar  plates22. 
Electron transport chain SCVs have been associated with reduced susceptibility towards multiple AMPs, includ-
ing hBD2-323, thrombin-induced platelet microbicidal  protein24 and  nisin24. We recently reported that inactiva-
tion of genes encoding for multiple subunits of the ATP synthase sensitizes S. aureus towards  polymyxins25, a 
class of cationic AMPs that is used for treatment of Gram-negative  infections26. The ATP synthase basically serves 
two physiological functions, first being synthesis of ATP from ADP and inorganic phosphate by using energy 
from the proton motive force. Secondly, during conditions with a low proton-motive force the ATP synthase can 
work in reverse as an ATPase and thereby contributes to the establishment of a cross-membrane proton gradient 
through ATP  hydrolysis27. In S. aureus, the ATP synthase is primarily used to hydrolyze ATP for maintaining the 
cross-membrane proton gradient both under fermentative and respiratory  conditions28. ATP synthase inactiva-
tion in S. aureus leads to hyper-polarization of the  membrane25,28, which was hypothesized to be the mechanism 
for sensitizing ATP synthase mutants towards  polymyxins25.
Several molecules have been shown to inhibit the ATP synthase in different  species29. For example inhibi-
tion of the ATP synthase with oligomycin A sensitizes S. aureus towards polymyxin  B25 and  aminoglycosides30. 
However, oligomycin A displays similar 50% inhibitory concentration  (IC50) between S. aureus and human 
mitochondrial ATP  synthases31, and cannot be used clinically due to toxicity  issues32. Resveratrol is a widely 
used nutraceutical that has been shown to bind to the bovine ATP synthase in the  F1-domain33 and also binds 
reversibly to the ATP synthase in E. coli, partially inhibiting both ATP hydrolysis and ATP  synthesis34. Co-
administration of resveratrol sensitizes S. aureus towards  aminoglycosides30. However, resveratrol is readily 
metabolized following oral administration, which probably only enables topical  use35.
Since ATP synthase inactivation sensitizes S. aureus towards polymyxins, we hypothesize that this strategy also 
can sensitize S. aureus towards various human AMPs. Potentiation of human AMPs that are currently ineffective 
against S. aureus may potentially become a new therapeutic strategy, where treatment relies on deprivation of 
AMP resistance mechanisms and hence boosting of the naturally occurring AMPs of the innate immune system.
Materials and Methods
Bacterial strains, growth conditions and chemicals. The Staphylococcus aureus JE2 wild type (WT) 
strain and derivative mutants used in this study are highlighted in Table 1. Antimicrobial peptides used in this 
study included histatin-5 (Innovagen, Sweden), LL-37 (Isca Biochemicals, United Kingdom) and hBD1-4 (Inno-
vagen, Sweden), as well as polymyxin B Etests (bioMérieux, France). We used the ATP synthase inhibitor res-
veratrol (Santa Cruz Biotechnology). Bacterial strains were routinely cultured at 37 °C in tryptic soy broth (TSB) 
or on tryptic soy agar (TSA).
Antimicrobial susceptibility assays. Microdilution. The minimum inhibitory concentration for res-
veratrol was determined using a two-fold broth microdilution assay in TSB (100 µl) with an initial inoculum of 
approximately 5 × 105 cells/ml. MIC was determined upon incubation at 37 °C for 24 h.
Etest. The MIC for polymyxin B was determined using Etest (bioMérieux, France) in the absence and in the 
presence of sub-inhibitory concentrations (0.0625x–0.25 × MIC) of resveratrol or menadione (1 µg/ml, Sigma). 
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From overnight cultures, strains were diluted to approximately  108 CFU/ml and then distributed on TSA plates 
using a sterile cotton swab. MIC was determined upon incubation at 37 °C for 24 h.
Bacterial cell survival assays. From overnight cultures of S. aureus JE2 and mutants, 10 μl was diluted into 
990 μl fresh TSB medium in a falcon tube and grown for 2 h for the cells to reach early exponential phase. After 
2  h the cultures were re-suspended in 10  mM sodium phosphate buffer (pH 7.4), termed NaPi (Medicago, 
Sweden). Cells were subsequently diluted in NaPi to approximately 5 × 105 CFU/ml, and combined with antimi-
crobial peptides and resveratrol when indicated, to a final volume of 100 µl and incubated in 96-well plates with 
shaking for 2 h at 37 °C. Bacteria were plated for CFU on TSA plates. Following overnight incubation at 37 °C 
for 24 h, viable cells were enumerated and relative cell survival was calculated as  CFUwith peptide/CFUwithout peptide 
at 2 h post-exposure. Values provided are the mean ± SEM derived from at least three independent biological 
replicates.
isolation of pMns from human blood. Blood was collected from healthy adult volunteers and written 
informed consent was given. Isolation of neutrophils was performed following the procedure described  in36. All 
methods were carried out in accordance with relevant guidelines and regulations. The institutional review board 
(IRB) of the University of Tübingen approved the study and all adult subjects provided informed consent. This 
study was done in accordance with the ethics committee of the medical faculty of the University of Tübingen that 
approved the study, Approval number 015/2014 BO2. Briefly, heparinized blood was diluted 1:1 (v/v) with PBS 
containing 0.5% BSA and 2 mM EDTA and layered onto a gradient of Biocoll (density, 1.077 g/ml; Biochrom) 
and Histopaque (density, 1.119 g/ml; Sigma). After centrifugation for 20 min at 380×g, neutrophils were col-
lected from the Histopaque phase. Cells were subjected to a brief hypotonic shock with ultrapure-water contain-
ing 155 mM ammonium chloride, 1 mM potassium hydrogen carbonate and 0.1 mM EDTA at pH 7.4, washed, 
and suspended at 2.5 × 106 cells/ml in RPMI containing 200 mg/ml HSA, 2 mM glutamine, 2 mM sodium pyru-
vate and 10 mM HEPES.
phagocytosis of S. aureus by neutrophils. Starter cultures of S. aureus JE2 and its respective atpA 
mutant were grown in TSB medium overnight. Main cultures were subsequently inoculated at an  OD600 of 0.1 
and grown to an OD of 1.  109 CFU of WT and atpA mutant cells were adjusted in PBS, stained with 10 µM car-
boxyfluorescein succinimidyl ester (CFSE) for 1 h at 37 °C and subsequently washed 3 times with PBS.  108 CFU/
ml were opsonized with 10% normal human serum (NHS) in RPMI for 1 h at 37 °C. To check for correct CFUs, 
the dilution was plated onto TSA agar plates. 2.5 × 106 previously isolated PMNs were seeded in a 96 well round-
bottom plate and challenged with opsonized WT and atpA mutant S. aureus JE2 at a MOI of 1. Incubation was 
performed for 20 min or 1 h at 37 °C. After incubation, the plate was centrifuged at 300×g for 10 min, and the 
pellet was fixed with 3.7% formaldehyde for 20 min in the dark. The fixed cells were then washed and suspended 
in PBS. The samples were analyzed with a BD FACSCalibur by measuring 5000 events for each sample.
Killing of S. aureus by neutrophils. Starter cultures of S. aureus JE2 and its respective atpA mutant were 
grown in TSB medium overnight. Main cultures were subsequently inoculated at an  OD600 of 0.1 and grown to 
an OD of 1.  109 CFU of WT and atpA mutant cells were adjusted in PBS medium, then washed and resuspended 
in PBS.  108 CFU/ml were opsonized with 10% normal human serum (NHS) in RPMI for 1 h at 37 °C. 2.5 × 106 
previously isolated PMNs were seeded in 96 well round-bottom plates and challenged with opsonized WT and 
atpA mutant S. aureus JE2 at a MOI of 1. Incubation was performed for 1 h at 37 °C in a 96 well round-bottom 
plate and inoculation controls were included. After incubation, the plate was centrifuged at 300×g for 10 min, the 
supernatants were collected, and the remaining neutrophil pellets were lysed using cold  ddH20 for 10 min on a 
rocker. The lysed neutrophils and remaining bacteria were resuspended and pooled with the previously collected 
supernatants. Dilutions of  10–2 were plated on TSA plates with an Eddy Jet 2 W and incubated overnight at 37 °C. 
Values provided are the mean ± SEM derived from at least seven independent biological replicates.
Statistics. The data were analyzed in GraphPad Prism 7 (GraphPad Software Inc.) using paired t-tests or 
one-way analysis of variance (ANOVA) with a post hoc analysis of Dunnett’s multiple comparison tests. Log-
transformed data was used for bacterial survival. P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***).
Table 1.  Strains and mutants used.
Organism Description and genotype Source
S. aureus JE2, CA-MRSA USA300
S. aureus JE2 menD::ΦNΣ 60
S. aureus JE2 atpA::ΦNΣ 60
S. aureus JE2 atpB::ΦNΣ 60
S. aureus JE2 atpG::ΦNΣ 60
S. aureus atpA+—Strain with allelic exchange of the transposon insertion (atpA::ΦNΣ) with the intact atpA gene 25
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Results
ATP synthase mutants are more susceptible to hBD2 and hBD4. Since inactivation of the ATP 
synthase increases susceptibility of S. aureus towards the antimicrobial peptides,  polymyxins25, we wondered if 
inactivation of the ATP synthase also sensitizes S. aureus towards AMPs of the human innate immune system. 
Therefore, bacterial killing of the WT S. aureus JE2 and isogenic atpA (ATP synthase subunit alpha) transposon 
mutant was assessed following 2 h exposure to human cationic AMPs, comprising histatin-5, LL-37 and hBD1-4 
at the concentrations highlighted in Fig. 1a. The atpA mutant was more susceptible to hBD4 and hBD2 com-
pared with the WT (Fig. 1a). The atpA mutant displayed a 63-fold greater reduction in viable cells compared 
with WT upon treatment with hBD4. For hBD2, the atpA mutant displayed a fivefold greater reduction in viable 
cells compared with WT. A minor increase in bactericidal activity against the atpA mutant was detected for 
histatin-5 and LL-37, whereas no differences between WT and atpA survival were detected upon treatment with 
hBD1 nor hBD3.
We assessed hBD4-mediated killing of other ATP synthase mutants, namely atpB (ATP synthase subunit A) 
and atpG (ATP synthase subunit gamma) and both mutants displayed increased susceptibility to hBD4, similarly 
to the atpA mutant (Fig. 1b).
Since the atpA mutant has a hyperpolarized  membrane25, we also assessed hBD4 susceptibility of the menD 
transposon mutant, which has a depolarized  membrane37. The menD mutant was indeed more tolerant to hBD4 
compared with WT, as no reduction in viable cell count was observed following 2 h exposure to hBD4 at 5 µM 
(Fig. 1b), suggesting that the magnitude of the membrane potential is an important determinant for hBD4 
susceptibility.
Figure 1.  ATP synthase mutants are more susceptible to specific human AMPs than the WT. (a) The 
susceptibilities to the different AMPs assayed are presented as the relative survival following 2 h exposure at the 
indicated AMP concentrations for JE2 (WT) and atpA mutant. (b) Survival of ATP synthase mutants (atpA, 
atpB and atpG) and menD mutant following 2 h exposure to hBD4 (5 µM). Each survival value provided is the 
mean ± SEM derived from at least three independent measurements. ★p < 0.05, ★★p < 0.01 and ★★★p < 0.001.
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Similarly we observed this correlation between magnitude of membrane potential and polymyxin B suscepti-
bility, where the menD mutant was more resistant towards polymyxin B compared with the WT (Supplementary 
Table S1). The menD mutant is auxotrophic for menadione and supplementation with the compound re-sensitized 
the menD mutant to polymyxin B (Supplementary Table S1).
Taken together, inactivation of the ATP synthase sensitizes S. aureus to specific human AMPs and the mag-
nitude of the membrane potential correlates with hBD4 susceptibility. This correlation also applies more broadly 
to include the non-human AMP, polymyxin B.
the Atp synthase inhibitor resveratrol sensitizes S. aureus towards hBD4. Resveratrol is a puta-
tive ATP synthase inhibitor in S. aureus30 and therefore, we assessed if resveratrol could sensitize S. aureus JE2 
towards hBD4. Resveratrol has growth-inhibitory properties with a MIC of 256 µg/ml, but at a sub-inhibitory 
concentration (0.125 × MIC) it had no impact on S. aureus viability (Fig. 2). Importantly, however, when sup-
plemented in combination with hBD4, resveratrol increased killing of WT S. aureus by 20-fold compared with 
hBD4 alone.
Similarly, supplementation of resveratrol at sub-inhibitory concentrations (0.0625x–0.25 × MIC) sensitized 
S. aureus JE2 to polymyxin B (Supplementary Table S2).
These result suggests that ATP synthase inhibition with resveratrol may be an attractive approach to sensitize 
S. aureus towards hBD4.
the atpA mutant is more susceptible to killing by human neutrophils. Log-phase bacteria of the 
WT and atpA mutant were opsonized with pooled normal human serum, phagocytosed by neutrophils, and sub-
sequently incubated for one hour before determination of surviving cells. The atpA mutant was more susceptible 
to neutrophil killing than the WT and after one hour of incubation with neutrophils, only 39.2% of the atpA cells 
survived compared with 49.9% for the WT (P = 0.006) (Fig. 3). The uptake of the strains into the neutrophils was 
similar (Data not shown), suggesting that the increased killing of the atpA is due to antimicrobial activities of the 
neutrophils and not due to alterations in phagocytosis rates.
As neutrophils normally use both, oxygen-dependent and non-oxygen-dependent killing mechanisms, includ-
ing antimicrobial  peptides38, we compared survival of atpA and WT in neutrophils treated with the NADPH 
oxidase inhibitor diphenyleneiodonium (DPI), which suppresses the formation of reactive oxygen  species18. 
Suppression of the oxidative burst limited killing of S. aureus (Fig. 3). After one hour incubation only 74.3% of 
the atpA cells survived in DPI-treated neutrophils, compared to 91.4% for the WT (P = 0.0196) (Fig. 3). These 
data suggest that the atpA mutant is more susceptible towards the oxygen-independent antimicrobial activities 
of neutrophils.
Discussion
Antimicrobial peptides are an important part of the innate immune system and the AMPs display activity 
against a wide range of bacterial-, fungal- and viral  species6. Several human AMPs however display low inhibi-
tory activity against S. aureus14. For example, the human β-defensins 1–4 are produced by keratinocytes and are 
key in protecting against skin  infections6. hBD3 displays greater bactericidal activity against S. aureus than the 
other β-defensins14–16, and hBD3 is important for keratinocytes in killing S. aureus17. Production of AMPs in 
the skin and in the nasal passages plays a major role in preventing S. aureus persistent colonization and people 
with defects in hBD3 production have enhanced nasal colonization of S. aureus39. Our results point to a novel 
Figure 2.  Resveratrol sensitizes S. aureus to hBD4. Survival of S. aureus JE2 was assessed for resveratrol (32 µg/
ml) and hBD4 (5 µM), either alone or in combination. Each value provided is the mean ± SEM derived from at 
least three independent measurements. ★p < 0.05, ★★p < 0.01 and ★★★p < 0.001.
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type of antimicrobial therapy, whereby the susceptibility of the pathogen is enhanced towards the natural human 
antimicrobial peptides. Here we demonstrate the potential for S. aureus, but it may be applicable to other human 
pathogens as well.
The energetic state of bacterial membranes can affect the susceptibility towards AMPs in different bacterial 
 species8 and for some conventional classes of antibiotics as well, i.e.  aminoglycosides40. Recently, we demonstrated 
that ATP synthase mutants of S. aureus become more sensitive towards  polymyxins25. ATP synthase inactivation 
confers hyperpolarization of the  membrane25,28 and larger membrane potentials can facilitate AMP insertion 
into  membranes8. In this study, we demonstrate that the activities of certain human AMPs are affected by the 
magnitude of the membrane potential. ATP synthase mutants have a hyperpolarized  membrane25,28 and become 
more sensitive towards hBD2 and hBD4 and to a minor degree towards LL-37 and histatin-5 (Fig. 1a). Contrarily, 
a menD mutant with a depolarized membrane is less sensitive towards hBD4 (Fig. 1b).
Our finding that membrane depolarization protects S. aureus from hBD4-mediated killing corroborate pre-
vious studies demonstrating that S. aureus SCVs are less susceptible to different AMPs. For S. aureus, electron-
transport chain deficient mutants are less susceptible to killing by thrombin-induced PMP-1 (tPMP-1)41,  nisin24, 
lactoferrin  B42 and human AMPs, including hBD2, hBD3 and LL-3723. Another study, with genetically defined 
menD and hemB mutants in different S. aureus genetic backgrounds did however not observe changes in sus-
ceptibility to LL-3743. Killing by the human neutrophil defensin 1 (hNP-1) is similar in WT and mutants with 
impaired electron transport  chains24,41,44. These observations indicate that membrane potential changes only 
affect the activity of specific AMPs.
It has been suggested that membrane depolarization and subsequently increased tolerance towards AMPs of 
the innate immune system is a survival strategy that enable intracellular persistence of S. aureus in eukaryotic 
 cells45. Here we demonstrate that inactivation of the ATP synthase contrarily sensitizes S. aureus to neutrophil-
killing (Fig. 3). The increased susceptibility to neutrophil-killing is also evident when the oxidative burst is 
suppressed (Fig. 3), suggesting that this effect is mediated by increased susceptibility to AMPs produced by 
 neutrophils38.
It is not only in S. aureus that AMP sensitivity is modulated by the magnitude of the membrane potential. In 
E. coli, inactivation of the ATP synthase also leads to hyperpolarization of the  membrane46 and ATP synthase 
mutants are more sensitive to  colistin47 and  aminoglycosides40,47. Deletion of the gene phoP in E. coli conferred 
hyperpolarization of the membrane and a concomitant increase in activity of polymyxin B, while collapsing the 
proton gradient with the protonophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP) abrogated this 
 effect48. Dissipation of membrane potential with CCCP also impaired killing of E. coli with the AMP  indolicidin49. 
For Salmonella enterica Typhimurium, impairment of the electron transport chain reduces AMP activity, e.g. a 
hemB mutant displays a fourfold increase in MIC for  colistin50. Even respiration-deficient mutants of the fungus 
Candida albicans experience reduced sensitivity to histatin-5 and chemical inhibition of the electron transport 
chain with sodium azide or CCCP treatment also protects C. albicans against histatin-5  killing51,52.
Figure 3.  Neutrophil-mediated killing of S. aureus. The percentage of viable opsonized WT and atpA 
mutant cells following incubation with neutrophils (PMN) for 1 h. Surviving cells are expressed in percentage 
of the initial counts. Diphenyleneiodonium (DPI) is a NADPH oxidase inhibitor. Each value provided 
is the mean ± SEM derived from at least seven independent measurements. ★p < 0.05, ★★p < 0.01 and ★★★p < 0.001.
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The ATP synthase may potentially be targeted to facilitate killing by AMPs of the innate immune system and 
hence be essential under in vivo conditions. By employing the Tn-seq methodology, the ATP synthase has been 
identified in several studies as essential during in vivo conditions, such as in abscess formation or osteomyelitis, 
while the ATP synthase is dispensable during growth in laboratory  medium53–55. Recently, Grosser and colleagues 
demonstrated that an ATP synthase mutant indeed is severely attenuated in a murine skin abscess  model28. 
ATP synthase inactivation confers pleiotropic effects, including attenuated growth under anaerobic conditions, 
increased sensitivity towards peroxide and nitric oxide  stresses28. Whether virulence attenuation of the ATP 
synthase mutant in the murine skin abscess model is mediated by a single phenotypic trait or a combination 
thereof remain unexplored in the  study28 and here we provide an additional phenotype that may contribute to the 
attenuated virulence, namely increased sensitivity of S. aureus to different AMPs of the innate immune system.
Inhibition of the ATP synthase may potentially have therapeutic value either as a monotherapy or in combi-
nation with AMPs or aminoglycosides. Many ATP synthase inhibitors have been  identified29, however several 
of these, e.g. oligomycin A, are not selective for bacterial ATP synthases and also blocks human mitochondrial 
ATP  synthases31. The ATP synthase has been clinically validated as a druggable target in recent years with the 
antibiotic bedaquiline that selectively inhibits ATP synthases of  Mycobacteria56. We demonstrated that the ATP 
synthase inhibitor resveratrol, a commonly used  nutraceutical57, sensitizes S. aureus towards hBD4 (Fig. 2). Res-
veratrol has previously been assessed for clearance of acne skin  lesions58 and has recently been shown to reduce 
abscess formation by S. aureus when used as a  monotherapy59. It will be important in future animal experiments 
to elucidate, whether resveratrol in combination with human defensins are superior in treating topical S. aureus 
infections compared with the respective monotherapies.
It is encouraging that bacterial ATP synthases are sufficiently different from human ATP synthases, which 
enables identification of selective bacterial ATP synthase inhibitors that are not toxic to human  cells32. Selec-
tive staphylococcal ATP synthase inhibitors may provide a novel class of antibacterial therapies that is based 
on sensitizing S. aureus towards the AMPs of the innate immune system. Additionally, such inhibitors can be 
adjuvants that potentiate the activity of conventional antibiotics, such as aminoglycosides and  polymyxins25,30. 
Several AMPs are in clinical  development3, whose activity potentially also can be enhanced by co-administration 
of ATP synthase inhibitors.
In summary, we have investigated the possibility of sensitizing S. aureus towards human AMPs by targeting 
the ATP synthase and our results suggest that it may be a novel strategy for development of new antimicrobial 
therapeutics.
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